KEYTRUDA’s recent success in triple-negative breast cancer validates I-SPY 2 adaptive platform approach to phase II clinical trials August 7, 2019
Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity & differential therapeutic responses August 2, 2019